BETA

Activities of Antonio LÓPEZ-ISTÚRIZ WHITE related to 2008/2133(INI)

Legal basis opinions (0)

Amendments (5)

Amendment 3 #
Draft opinion
Recital B a (new)
Ba. whereas, in the case of patents on pharmaceutical products, whilst infringements of patents are settled case- by-case on the basis of substantive arguments made in civil proceedings on the grounds of a patent infringement, infringements of copyright and trademarks constitute intentional offences,
2008/10/01
Committee: JURI
Amendment 7 #
Draft opinion
Paragraph 2 a (new)
2a. Considers it important that international initiatives such as ACTA that are taken to combat counterfeiting and piracy should not lead to the adoption of more stringent patent-protection measures that go beyond the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS);
2008/10/01
Committee: JURI
Amendment 14 #
Draft opinion
Paragraph 6 a (new)
6a. Calls on the Commission to guarantee, in line with Parliament's position and Article 61 of the TRIPS Agreement1 , that ACTA will be restricted to promoting criminal measures applicable to copyright and trademark infringements, and that such measures will not cover the area of patents;
2008/10/01
Committee: JURI
Amendment 16 #
Draft opinion
Paragraph 6 b (new)
6b. Calls on the Commission to guarantee – as is already the case under Article 3(2)2 of Directive 2004/48/EC on the enforcement of intellectual property rights - that measures promoted at international level to combat counterfeiting and piracy will be applied in such a way as to avoid creating barriers to legitimate trade; considers that, in addition, safeguards should be put in place against any abuse of these measures;
2008/10/01
Committee: JURI
Amendment 18 #
Draft opinion
Paragraph 8 a (new)
1 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ L 145, 31.5.2001, p. 43). 2 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliam8a. Supports, as regards the area of public health, the WHO definition of counterfeit medicine: “a medicine which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, Council and Commission documents (OJ L 145, 31.5.2001, p. 43).without active ingredients, with insufficient active ingredients or with fake packaging.” Or. es
2008/10/01
Committee: JURI